Journal
FRONTIERS IN ONCOLOGY
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.671044
Keywords
glioblastoma; radiotherapy; immunotherapy; antigenicity; adjuvanticity; immunosuppression
Categories
Funding
- National Cancer Institute (NCI) Stimulating Access to Research in Residency (StARR) Award [R38CA231577]
- Gary and Yael Fegel Family Foundation
- Matheson Foundation [UR010590]
- Herbert Irving Cancer Center Cancer Center Support Grant [P30CA013696]
- Swim Across America
- Hyundai Hope on Wheels Hope Scholar Award
- Department of Radiation Oncology at Weill Cornell Medicine
- Brain Cancer Research Investigator Grant from B*CURED
- Star and Storm Foundation
Ask authors/readers for more resources
Glioblastoma (GBM) is a highly aggressive brain tumor with poor prognosis. Immunotherapy has shown limited response as monotherapy in GBM, despite advances in the field. Recent discoveries offer insight into improving immunotherapy and exploring combinations with treatments like radiation to enhance prognosis in this devastating disease.
Glioblastoma (GBM) is among the most aggressive of brain tumors and confers a dismal prognosis despite advances in surgical technique, radiation delivery methods, chemotherapy, and tumor-treating fields. While immunotherapy (IT) has improved the care of several adult cancers with previously dismal prognoses, monotherapy with IT in GBM has shown minimal response in first recurrence. Recent discoveries in lymphatics and evaluation of blood brain barrier offer insight to improve the use of ITs and determine the best combinations of therapies, including radiation. We highlight important features of the tumor immune microenvironment in GBM and potential for combining radiation and immunotherapy to improve prognosis in this devastating disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
